CSI Market
Sign In | Register

Neuropace Inc (NPCE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NPCE Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how Neuropace Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-12.93
Depreciation & amortization0.13
Amortization of Other Assets0.14
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase1.50
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation4.58
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Increase Decrease In Non Cash Interest Expense0.08
Increase Decrease In Contract With Customer Liability-0.02
Follow On Offering Costs Included In Accounts Payable And Accrued Liabilities-
Debt Issuance Costs Included In Accounts Payable And Accrued Liabilities-
Deferred Offering Costs Offset Against Additional Paid In Capital-
Capital Expenditures Incurred But Not Yet Paid0.11
Increase Decrease In Accrued Liabilities Early Exercise Of Options-
Increase Decrease In Operating Lease Liability-0.51
Income taxes0.00
Gain (Loss) on Sale of Investments-0.21
Increase (Decrease) in Accounts Receivable0.25
Increase (Decrease) in Accounts Payable1.98
Increase (Decrease) in Accrued Liabilities-2.49
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.01
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.81
Discontinued operations0.04
Net Cash flow from Operating Activities-9.80
Investing Activities
Capital Expenditures-0.24
Sale of Capital Items0.00
Proceeds from Sale of Short-term Investments0.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.24
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.39
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.23
Other net-0.15
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents21.81
Proceeds From Issuance Of Common Stock Net Of Sales Commissions And Offering Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.01
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-10.05
Total Cash Flow-9.04
4 historic quarters locked

Sign in to unlock the full Neuropace Inc cash flow history.

Sign In Create Free Account

About Neuropace Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001528287-26-000030

Figures are derived from filed reports and may be restated. Historical data is subject to revision.